54730-35-7

Basic information

• Product Name: 3,5-Dichloro-4-methylaniline
• Synonyms: 3,5-Dichloro-4-methylaniline;3,5-Dichloro-4-methylbenzenamine;BenzenaMine, 3,5-dichloro-4-Methyl-
• CAS NO: 54730-35-7
• Molecular Formula: C₇H₇Cl₂N
• Molecular Weight: 176.05
• Mol File: 54730-35-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 57-59 °C
• Boiling Point: 284.6 °C at 760 mmHg
• Flash Point: 125.9 °C
• Appearance: /
• Density: 1.334g/cm³
• Vapor Pressure: 0.00295mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.92±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dichloro-4-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloro-4-methylaniline(54730-35-7)
• EPA Substance Registry System: 3,5-Dichloro-4-methylaniline(54730-35-7)

Safety Data

• Hazardous Substances Data: 54730-35-7(Hazardous Substances Data)

Usage

General Description

3,5-Dichloro-4-methylaniline, also known by its IUPAC name 3,5-dichloro-4-methyl-phenylamine, is a chemical compound with the molecular formula C7H7Cl2N. It is classified as an aromatic amine and is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. 3,5-Dichloro-4-methylaniline is a white to light beige crystalline solid at room temperature, and it has a strong, unpleasant odor. 3,5-Dichloro-4-methylaniline is considered to be potentially hazardous, as it can cause skin and eye irritation upon contact and may be harmful if ingested or inhaled. It is important to handle and store this chemical with proper care and in accordance with safety guidelines.

InChI:InChI=1/C7H7Cl2N/c1-4-6(8)2-5(10)3-7(4)9/h2-3H,10H2,1H3

Upstream product

• 121-86-8 2-chloro-4-nitrotoluene 
• 99-99-0 1-methyl-4-nitrobenzene 
• 7149-69-1 1,3-dichloro-2-methyl-5-nitrobenzene 

Downstream Products

• 956319-67-8 1-(4-bromo-2,6-dichloro-benzyl)-3-piperidin-1-yl-pyrrolidin-2-one 
• 956123-16-3 2-(4-bromo-2,6-dichloro-benzyl)-2-aza-spiro[4.5]decan-1-one 
• 1533424-25-7 N³-(3,5-dichloro-4-methylphenyl)-1H-[1,2,4]triazole-3,5-diamine 
• 1533434-93-3 (Z)-methyl N'-cyano-N-(3,5-dichloro-4-methylphenyl)carbamimidothioate 
• 1533425-15-8 1,3-dichloro-5-isothiocyanato-2-methylbenzene 
• 1436865-13-2 C₂₂H₂₇Cl₂N₃O₂ 
• 177167-51-0 2,6-dichloro-4-iodobenzyl acetate 
• 177167-62-3 2,6-dichloro-4-<(trimethylsilyl)ethynyl>benzaldehyde 

Relevant articles and documents

Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7)

Here, we report the discovery of a new class of NPBWR1 antagonists identified from a fragment-based screen. Compound 1 (cAMP IC50 = 250 μM; LE = 0.29) emerged as an initial hit. Further optimization of 1 by SAR-by-catalogue and chemical modification produced 21a (cAMP IC50 = 30 nM; LE = 0.39) with a 6700-fold increase in potency from fragment 1. Somewhat surprisingly, Schild analysis of compound 21a suggested that in vitro inhibition of NPW-mediated effects on upon cAMP accumulation were saturable, and that compound 21a dose-dependently increased [125I]-hNPW23 dissociation rate constants from NPBWR1 in kinetic binding studies. Collectively, these data are inconsistent with a classic surmountable, orthosteric mechanism of inhibition. The benzimidazole inhibitors reported herein may therefore represent a mechanistically differentiated class of compounds with which to form a better appreciation of the pharmacology and physiological roles of this central neuropeptide system.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377